e-Therapeutics, the systems biology drug discovery company, today announces the first day of trading of its Ordinary Shares on the AIM market of the London Stock Exchange (“AIM”). WH Ireland is acting as Nominated Adviser and Cornhill Asset Management as Broker. The market epic code is ETX.

A placing of 1,985,075 Ordinary Shares at 67 pence each has raised £1.33 million (gross) for the Company. The total issued share capital of the Company is 55,710,103 and the market capitalisation of the Company at the Placing Price following Admission will be £37.33 million.

Commenting on the Placing and Admission, Professor Malcolm Young, Chief Executive Officer of e-Therapeutics, said: “We are delighted by the response of investors to the flotation of e-Therapeutics. The funds raised will enable us to develop and broaden our drug development pipeline, and will significantly raise the profile of e-Therapeutics with potential licensing partners. I would like to thank all of our investors for recognising the exciting opportunity that lies ahead.”

Terms used in this announcement have the same meanings as the defined terms in the Company’s Admission Document dated 22 November 2007, which is available on the Company’s website (www.etherapeutics.co.uk).

For the full press release, please click here.